m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT03116
 [1]
m6A modification MALAT1 MALAT1 METTL14 Methylation : m6A sites Indirect Enhancement Histone modification Regulated Target KDM2A Downstream Gene
m6A Modification:
m6A Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
m6A Target Metastasis associated lung adenocarcinoma transcript 1 (MALAT1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Histone modification (HistMod)
Epigenetic Regulator Lysine-specific demethylase 2A (KDM2A) ERASER View Details
Crosstalk Relationship m6A  →  Histone modification Enhancement
Crosstalk Mechanism m6A modification indirectly regulates histone modification through downstream signaling pathways
Crosstalk Summary Overall, our findings verified the therapeutic role of silencing METTL14 in OSCC treatment through the Metastasis associated lung adenocarcinoma transcript 1 (MALAT1)/miR-224-5p/KDM2A axis
Responsed Disease Oral squamous cell carcinoma ICD-11: 2B6E.0
 Disease Info 
Cell Process Cell proliferation
In-vitro Model
 Hs 680.Tg Normal Homo sapiens CVCL_0842
SCC-15 Tongue squamous cell carcinoma Homo sapiens CVCL_1681
SCC-25 Tongue squamous cell carcinoma Homo sapiens CVCL_1682
CAL-27 Tongue squamous cell carcinoma Homo sapiens CVCL_1107
FaDu Hypopharyngeal squamous cell carcinoma Homo sapiens CVCL_1218
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Lysine-specific demethylase 2A (KDM2A) 2 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name daminozide Investigative [2]
Synonyms
DMASA; SADH; B 995; Alar; Kylar; B-NINE
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1500 nM
External Link
CID: 15331
TTD: D0B2WZ
 Compound Name IOX2 Investigative [3]
Synonyms
compound 6
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 54685215
TTD: D0WA3E
2B6E: Head and neck squamous carcinoma 3 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name OraTest Approved [4]
External Link
TTD: D00DCY
 Compound Name Contusugene ladenovec Phase 3 [5]
Synonyms
Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR
    Click to Show/Hide
External Link
TTD: D04FYL
 Compound Name INGN-234 Discontinued in Phase 2 [6]
Synonyms
P53 tumor suppressor (topical formulation), Introgen
    Click to Show/Hide
External Link
TTD: D05AHK
References
Ref 1 Mechanism of METTL14 and m6A modification of lncRNA MALAT1 in the proliferation of oral squamous cell carcinoma cells. Oral Dis. 2022 Apr 25. doi: 10.1111/odi.14220. Online ahead of print.
Ref 2 Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases. J Med Chem. 2012 Jul 26;55(14):6639-43.
Ref 3 Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases. ACS Chem Biol. 2013 Jul 19;8(7):1488-96.
Ref 4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 5 ClinicalTrials.gov (NCT00041613) Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate. U.S. National Institutes of Health.
Ref 6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028790)